Genetic risk factors for chronic obstructive pulmonary disease

Swiss Medical Weekly

Volumn 132, Issue 3-4, 2002, Pages 27-37

  Joos, Ladina ^a   Paré, Peter D ^a   Sandford, Andrew J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Genetics; Polymorphisms

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BETA 2 ADRENERGIC RECEPTOR; CYTOCHROME P450 1A1; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE; PROTEINASE; PROTEINASE INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D BINDING PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE COURSE; GENE; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MUCOCILIARY CLEARANCE; PATHOGENESIS; REVIEW; RISK FACTOR; XENOBIOTIC METABOLISM;

EID: 0037176654     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. The natural history of chronic airflow obstruction
2. Smoking and lung function
3. The familial occurrence of chronic obstructive pulmonary disease
4. Studies of the familial aggregation of chronic bronchitis and obstructive airways disease
5. Family aggregation of pulmonary function measurements
6. Genetic-environmental interactions in chronic airways obstruction
7. Familial occurrence of chronic respiratory disease and familial resemblance in ventilatory capacity
8. Familial aggregation of chronic respiratory disease: Use of National Health Interview Survey data for specific hypothesis testing
9. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study
10. Inherited risk factors for chronic lung disease
11. Genetic and environmental determinants of chronic obstructive pulmonary disease
12. A common familial component in lung cancer and chronic obstructive pulmonary disease
13. Household aggregation of pulmonary function and chronic bronchitis
14. Familial factors related to lung function in children aged 6-10 years. Results from the PAARC epidemiologic study
15. Family resemblance for normal pulmonary function
16. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins
17. Environmental versus genetics in determining bronchial susceptibility to cigarette smoking
18. Assessment of genetic and nongenetic influences on pulmonary function. A twin study
19. Pulmonary function in identical twins: Comparison of nonsmokers and smokers
20. Pulmonary function in identical twins raised apart
21. Genetic and environmental influences on pulmonary function in adult twins
22. Genetic influence on normal variability of maximum expiratory flow-volume curves
23. Genetic and environmental influences on pulmonary function in aging Swedish twins
24. Major genetic mechanisms in pulmonary function
25. Variance components analysis of forced expiration in families
26. Segregation analysis of pulmonary function among families in the Framingham Study
27. Segregation analysis of two lung function indices in a random sample of young families: The Humboldt Family Study
28. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis
29. The electrophorectic alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency
30. 1-antitrypsin deficiency
31. 1-antitrypsin deficiency
32. 1-antitrypsin
33. The abnormality of the S variant of human alpha-1-antitrypsin
34. Amino acid substitution Glu leads to Lys alpha-1-antitrypsin PiZ
35. Molecular abnormality of human alpha-1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency
36. Molecular basis of α1-antitrypsin deficiency
37. 1-antitrypsin deficiency of adults with pulmonary symptoms
38. Alpha 1 antitrypsin deficiency: The clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association
39. 1-antitrypsin deficiency in nonsmokers
40. Smoking, lung function, and alpha-1-antitrypsin deficiency
41. Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200,000 infants
42. Neonatal screening for alpha-1-antitrypsin deficiency
43. 1-antitrypsin deficiency with special reference to non-index cases
44. Decline in FEV1 related to smoking status in individuals with severe alpha-1-antitrypsin deficiency (PiZZ)
45. Variability of pulmonary function in alpha-1-antitrypsin deficiency: Clinical correlates
46. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha-1-antintrypsin deficiency
47. 1-antitrypsin deficiency
48. PI SZ phenotype in chronic obstructive pulmonary disease
49. 1-antitrypsin heterozygotes (Pi MZ) in patients with obstructive pulmonary disease
50. Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD)
51. 1-antitrypsin heterozygote controversy
52. 1-antitrypsin Pi types in COPD patients
53. 1-antirypsin Pi-types in 965 COPD patients
54. Prevalence of abnormal protease inhibitor phenotypes in patients with chronic obstructive lung disease
55. Protease inhibitors in chronic obstructive pulmonary disease
56. 1-antitrypsin gene and the risk of chronic obstructive pulmonary disease
57. Susceptibility genes for rapid decline of lung function in the Lung Health Study
58. Serum alpha-1-antitrypsin variants. Prevalence and clinical spirometry
59. 1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population
60. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community
61. Closing volume and flow volume abnormalities in alpha-1-antitrypsin phenotype groups in a community population
62. Pi phenotypes and the prevalence of chest symptoms and lung function abnormalities in workers employed in dusty industries
63. Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population
64. 1-antitrypsin deficiency: A case-control study
65. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects
66. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ
67. 1-antitrypsin gene are associated with chronic obstructive airways disease
68. 1-antitrypsin gene region in patients with chronic obstructive pulmonary disease
69. 1-antitrypsin gene and chronic obstructive pulmonary disease
70. Alpha(1)-antitrypsin Taq I polymorphism and alpha(1)-antichymotrypsin mutations in patients with obstructive pulmonary disease
71. 1-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequence
72. 1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factors
73. α1-antitrypsin genotypes and the acute-phase response to open heart surgery
74. Alpha-1-antitrypsin deficiency alleles and the Taq-I G→A allele in cystic fibrosis lung disease
75. 1-antitrypsin gene polymorphism related to respiratory system disease
76. 1-antitrypsin deficiency. Prevalence and clinical spectrum in asthmatic children
77. Mis-sense mutation of α1-antichymotrypsin gene associated with chronic lung disease
78. 1-antichymorrypsin mutations in patients with chronic obstructive pulmonary disease
79. 2-macroglobulin gene and detection of mutations in two functional domains: The bait region and the thiolester site
80. Matrix metalloproteinases
81. Fine physical mapping of the human matrix metalloproteinase genes clustered on chromosome 11q22.3
82. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization
83. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints
84. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region
85. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism
86. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema
87. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice
88. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD
89. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an ETS binding site and augments transcription
90. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease
91. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis
92. Shortened microsatellite d(CA)21 sequence downregulates promoter activity of matrix metalloproteinase 9 gene
93. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function
94. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants
95. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: Studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene
96. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema
97. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese
98. Genetic susceptability to chronic obstructive pulmonary disease in Koreans: Combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1
99. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer
100. Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis
101. Heterogeneous expression and polymorphic genotype of glutathione S-transferases in human lung
102. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons
103. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease
104. Relationship between genotype and function of the human CYP1A1 gene
105. Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer
106. Protective effects of heme oxygenase-1 in acute lung injury
107. Heme Oxygenase 1: Function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury
108. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema
109. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg
110. Vitamin D-binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes
111. Possible protective effect against chronic obstructive airways disease by the GC 2 allele
112. Vitamin D binding protein variants and the risk of COPD
113. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis
114. Secretion of tumour necrosis factor α and lymphotoxin a in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
115. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria
116. Tumour necrosis factor haplotypes and asthma
117. Prevalence of tumour necrosis factor-α and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma
118. Tumor necrosis factor-α gene polymorphism in chronic bronchitis
119. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease
120. Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease
121. No association of tumor necrosis factor-alpha gene polymorphism and copd in Caucasian smokers and Japanese smokers
122. Interleukin-1 receptor antagonist: Role in biology
123. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci
124. Duff GW Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta)
125. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat
126. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus
127. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus
128. An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata
129. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist
130. Severity of olopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene
131. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease
132. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1 beta genes
133. Association of IL-1 beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers
134. Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha polymorphisms are associated with susceptibility to COPD
135. Autonomic and airway reactivity in obligate heterozygotes for cystic fibrosis
136. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis
137. Sequence analysis of the cystic fibrosis gene in patients with disseminated bronchiectatic lung disease. Application in the identification of a cystic fibrosis patient with atypical clinical course
138. Sweat chloride and DF508 mutation in chronic bronchitis or bronchiectasis
139. Abnormal distribution of cystic fibrosis DF508 allele in adults with chronic bronchial hypersecretion
140. CFTR gene variant IVS8-5T in disseminated bronchiectasis
141. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease
142. CFTR gene mutations-including three novel nucleotide substitutions-and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease
143. Disseminated bronchiectasis and cystic fibrosis gene mutations
144. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Glyl 6 correlates with the nocturnal phenotype
145. Beta2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma
146. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects
147. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness
148. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing
149. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilotor pharmacodynamics
150. Beta(2)-adrenergic receptor arg16/arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites
151. Beta(2)-Adrenergic receptor polymorphisms and asthma
152. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor
153. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells
154. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
155. Family study of alpha-1-antitrypsin deficiency: Effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits